| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_238a0cbb4d846151b3a4844bad7f9879 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab2f602aa2a8735e2762c604ba49538f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae9c1edef2f76a9859ec20f1bb7aae5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44f5c6b6f9f28342242c2a5cf03573dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f36bf615804e2c1c39827d9c568f44f |
| publicationDate |
2019-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2019038829-A |
| titleOfInvention |
Treatment of neurodegenerative diseases by inhibition of Hsp90 |
| abstract |
PROBLEM TO BE SOLVED: To provide a method for treatment of a neurodegenerative disease, wherein a therapeutic agent that inhibits Hsp90 and is delivered to the brain is administered to an individual in need of such treatment. The flexibility necessary for the aryl ring or heteroaryl ring to have a purine moiety attached by a linker at the 8 or 9 position and the compound as a whole to be received in the N-terminal pocket of Hsp90 and Administering a therapeutically effective amount of a purine scaffold compound having a substituent, wherein the compound and mode of administration are selected such that the compound is delivered to the brain. [Selection figure] None |
| priorityDate |
2006-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |